Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided claim summary is consistent with the supplied FDA label excerpts: clindamycin should be used only for proven/strongly suspected susceptible bacterial infections and not for viral/nonbacterial infections, aligning with the INDICATIONS AND USAGE and PRECAUTIONS statements. No contradictions or omitted material safety elements are identifiable from the information provided.
Category Scores
Accurate Statements
Clindamycin Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria; prescribing in the absence of such infection is unlikely to provide benefit and increases risk of drug-resistant bacteria.
Section 1 (Indications and Usage) and Section 5 (PRECAUTIONS / General / Information for Patients): “should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria” and “Prescribing clindamycin injection in the absence of a proven or strongly suspected bacterial infection… is unlikely to provide benefit… and increases the risk of… drug-resistant bacteria.”
Antibacterial drugs including clindamycin should be used only to treat bacterial infections and do not treat viral infections.
Section 5 (PRECAUTIONS / General / Information for Patients): “They do not treat viral infections (e.g., the common cold).”
Unsupported Statements
Contradictions
Important Omissions
Boxed warning content regarding C. difficile-associated diarrhea/colitis was included in the prompt label excerpts but was not reflected in any explicit AI-generated clinical safety assertion within the provided text to be audited.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The only evaluated claims concern appropriate use for susceptible bacterial infections vs viral/nonbacterial infections, which is directly supported by the label excerpts provided. No contradictory or unsafe dosing/administration claims were present in the submitted text.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
No explicit mention of the boxed warning (C. difficile-associated diarrhea/colitis) in the provided claim text to evaluate.
Suggested Improvement
If producing a label-aligned response on safety, explicitly connect clindamycin use to considering CDAD risk and evaluating antibiotic-associated diarrhea/colitis as described in the boxed warning.